Sandvig-Pharma ApS: Financial statements 2022
CVR: 40667687
Source: annual report 2022, Danish Business Authority
01/07/2021 – 30/06/2022
Sandvig-Pharma ApS (CVR 40667687) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -423,235 and a net result of DKK -572,781 compared with DKK 0 the year before. Equity in the 2022 report amounted to DKK -522,968.
- Gross Profit
- DKK -423,235
- Profit/Loss
- DKK -572,781
- Equity
- DKK -522,968
- Total Assets
- DKK 353,873
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -423 t. | -573 t. | -523 t. | - |
| 2021 | - | - | 0 | 50 t. | - |
Official annual report
Keep an eye on Sandvig-Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of August 5, 2022, Lars Buchard Denker is registered as adm. dir. of Sandvig-Pharma ApS.
As of August 5, 2022, Jeannette Buchard Denker has stepped down as adm. dir. of Sandvig-Pharma ApS.
On August 4, 2022, the company changed its name from Z-Pharma ApS to Sandvig-Pharma ApS.
As of June 30, 2022, Sandvig Capital ApS is registered as an owner of Sandvig-Pharma ApS with an ownership share of 100%.
About Sandvig-Pharma ApS
Sandvig-Pharma ApS is a Danish company of the type Anpartsselskab based in Aabenraa, founded in 2019. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Z-Pharma ApS and Zibo Pharma ApS. The management consists of Lars Buchard Denker. The company is owned by Sandvig Capital ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -4,539,181 and a net result of DKK -3,988,029 compared with DKK -5,566,003 the year before. Equity in the 2025 report amounted to DKK -17,841,900.